Return to Provider News

Cost-Share for COVID-19 Treatment Resumes January 1, 2022

Audience: Hospitals

Our commitment to assisting members and providers through the many challenges faced during case surges and hospitalizations guided our business decision to continue the cost-share waiver for COVID-19 treatment for our fully insured members. Some of our self-funded groups also chose to extend the member cost-share waiver. 
With highly effective COVID-19 vaccines now widely available free of charge, significantly reducing the need for hospitalization, we will resume the collection of the member cost-share responsibility for COVID-19-related inpatient stays and monoclonal antibody treatment as of January 1, 2022 for fully insured members. 

Self-funded groups may have different cost-share waiver arrangements for COVID-19 treatment, so please check member benefits to determine member cost-share responsibility.   

If you have any questions, please contact your Provider Relations representative. 

Related News
Important Pay Cycle Information

Upcoming HEDIS® Medical Record Review for Out-of-Area Members

Information Related to NYS DFS Insurance Circular Letter No. 1 (2022)

Holiday Office Closure and Zelis® Payments Schedule Update

Updated Participating Provider Manual Now Available

Category

Excellus

Benefits & Eligibility

General Office Information

IE Browser Modal